Mariko Kurokawa,Wataru Gonoi,Shouhei Hanaoka et al. Mariko Kurokawa et al.

Materials and methods: This multicenter study included 52 patients with uterine sarcomas treated at three Japanese hospitals between 2007 and 2023.

Aruba Nawaz Khattak,Aymen Shahab,Fatima Israr et al. Aruba Nawaz Khattak et al.

Though uterine sarcomas can metastasize to unusual sites, paraspinal metastasis is almost unprecedented, emphasizing the need for thorough imaging and surveillance.

Jan Hojný,Jiří Dvořák,Romana Vránková et al. Jan Hojný et al.

Low-grade endometrial stromal sarcomas (LG-ESS), high-grade endometrial stromal sarcomas (HG-ESS), undifferentiated uterine sarcomas (UUS), and uterine tumors resembling ovarian sex cord tumors (UTROSCT) are distinct non-smooth muscle cell neoplasms with varying clinical outcomes often exhibiting overlapping

Gianna Barbara Cundari,Laura Feole,Corrado Terranova et al. Gianna Barbara Cundari et al.

However, their role in identifying uterine sarcomas remains debated. This systematic review and case series aims to examine the diagnostic and prognostic significance of CA125 and HE4 in uterine sarcomas....A case series of all uterine sarcomas treated at the Campus Bio-Medico Gynecology Unit of Rome from 2010 to 2020 was analyzed. Results: The analysis of the 11 selected studies allowed us to investigate the role of CA125 in uterine sarcomas.

Xuan Lan Nguyen,Quang Huy Huynh,Phuc Nhon Nguyen Xuan Lan Nguyen

Background: This study aims to describe the clinical and imaging characteristics of uterine sarcomas and the role of imaging modalities in assessing them....Some imaging features of uterine sarcomas were found including nontypical lesion of fibroid (89.7%), solitary mass (84.6%), inhomogeneous structure (76.9%), invisible endometrium (67.9%), moderate-rich vascularization on Doppler signal (57.7%), irregular border of tumor (48.7%), classification of FIGO...Conclusions: Besides clinical presentations, uterine sarcomas present some specific features on US.

Gulisa Turashvili,Edwin Choy,Adam S Fisch et al. Gulisa Turashvili et al.

Although this gene fusion has been described in other soft tissue neoplasms, it has not been previously reported in uterine sarcomas and highlights the significance of performing molecular analysis in uterine mesenchymal tumors with unusual morphology and/or immunophenotype.

Rita Trozzi,Sandra Tuyaerts,Daniela Annibali et al. Rita Trozzi et al.

However, stable disease was observed in three uterine sarcomas (median duration 12 weeks), three sex cord-stromal tumors (median duration 32 weeks), and four low-grade serous ovarian cancer patients (median duration 20 weeks), leading to a disease control rate of 100% for these tumor types.

Magdalena Steinlechner,Laura Strobel,Katharina Leitner et al. Magdalena Steinlechner et al.

Objective: The use of conventional doxorubicin in combination with trabectedin leads to a considerable prolongation of progression-free survival in the treatment of uterine sarcomas but is associated with dose-limiting toxicities....Methods: In this retrospective cohort study, the clinical outcome was analyzed in patients with advanced or recurrent uterine sarcomas with measurable disease treated with pegylated liposomal doxorubicin 30 mg/m2 plus trabectedin 1.5 mg/m2 given every 3 weeks between January 2011 and...Conclusion: Our study found an overall clinical benefit for the combination of pegylated liposomal doxorubicin plus trabectedin in metastatic uterine sarcomas of 43% and appears to exhibit a favorable toxicity profile which allows prolonged administration of this regimen.

Yukio Yamanishi,Yasushi Kotani,Aki Kido et al. Yukio Yamanishi et al.

Methods: Of 154 uterine sarcomas and 154 uterine fibroids treated at 15 centers between January 2006 and December 2020, 139 sarcomas (16 smooth muscle tumors of uncertain malignant potential) and 141 fibroids with diffusion-weighted imaging information were included in the analysis

Markus Wallwiener,Marco Johannes Battista,Eike-Christian Burandt et al. Markus Wallwiener et al.

Because of their rarity and heterogeneous histopathology, uterine sarcomas are challenging in terms of their clinical management, and treatment requires a multidisciplinary approach. Methods This S2k guideline was first published in 2015.